Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis

At the 24-week assessment, participants receiving risankizumab showed greater improvement in primary and secondary endpoints than did placebo with no new safety signals.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news